Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback